106 related articles for article (PubMed ID: 22473623)
1. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients.
Parker CC; Kim RH; Li BD; Chu QD
J Surg Oncol; 2012 Sep; 106(4):393-8. PubMed ID: 22473623
[TBL] [Abstract][Full Text] [Related]
2. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
[TBL] [Abstract][Full Text] [Related]
3. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.
Hiller DJ; Meschonat C; Kim R; Li BD; Chu QD
Surgery; 2011 Sep; 150(3):459-65. PubMed ID: 21878231
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
Mizell J; Smith M; Li BD; Ampil F; Chu QD
Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
8. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients.
Chu QD; Holm NT; Madumere P; Johnson LW; Abreo F; Li BD
Surgery; 2011 Feb; 149(2):193-9. PubMed ID: 20598333
[TBL] [Abstract][Full Text] [Related]
11. [Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer].
Wang Y; Yao L; Liu YQ; Xu Y; Ou YT; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):511-4. PubMed ID: 21029694
[TBL] [Abstract][Full Text] [Related]
12. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 membrane expression in node-negative breast cancer.
Blot E; Laberge-Le Couteulx S; Jamali H; Cornic M; Guillemet C; Duval C; Hellot MF; Pille JY; Picquenot JM; Veyret C
Breast J; 2008; 14(3):268-74. PubMed ID: 18373506
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
Wolfort R; de Benedetti A; Nuthalapaty S; Yu H; Chu QD; Li BD
Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
[TBL] [Abstract][Full Text] [Related]
15. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
[TBL] [Abstract][Full Text] [Related]
16. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
18. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
